<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03648385</url>
  </required_header>
  <id_info>
    <org_study_id>R01HL141268</org_study_id>
    <nct_id>NCT03648385</nct_id>
  </id_info>
  <brief_title>Effects of DHEA in Pulmonary Hypertension</brief_title>
  <acronym>EDIPHY</acronym>
  <official_title>Effects of DHEA in Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rhode Island Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rhode Island Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this crossover trial is to determine whether the study drug
      dehydroepiandrosterone (DHEA) improves right ventricular longitudinal strain measured by
      cardiac magnetic resonance imaging at 18 weeks compared to placebo and to assess side effects
      and safety in pulmonary arterial hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 9, 2019</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Right ventricular (RV) longitudinal strain</measure>
    <time_frame>18 weeks, 40 weeks</time_frame>
    <description>Change in global RV longitudinal strain measured by cardiac magnetic resonance imaging (MRI) between DHEA and placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>RV ejection fraction</measure>
    <time_frame>18 weeks, 40 weeks</time_frame>
    <description>Change in RV ejection fraction measured by cardiac MRI between DHEA and placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NT-proBNP</measure>
    <time_frame>2 weeks, 18 weeks, 24 weeks, 40 weeks</time_frame>
    <description>Change in serum level of NT-proBNP between DHEA and placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sex hormone levels</measure>
    <time_frame>2 weeks, 18 weeks, 24 weeks, 40 weeks</time_frame>
    <description>Change in sex hormone levels between DHEA and placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Six minute walk distance (6MWD)</measure>
    <time_frame>2 weeks, 18 weeks, 24 weeks, 40 weeks</time_frame>
    <description>Change in 6MWD between DHEA and placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>World Health Organization (WHO) Functional Class</measure>
    <time_frame>2 weeks, 18 weeks, 24 weeks, 40 weeks</time_frame>
    <description>Change in WHO Functional Class (I - IV with IV indicating worse symptoms) between DHEA and placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form-36</measure>
    <time_frame>2 weeks, 18 weeks, 24 weeks, 40 weeks</time_frame>
    <description>Change in Short Form-36 summary scores for physical and mental components (range 0 - 100, higher scores indicating better quality of life) between DHEA and placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>emPHasis-10</measure>
    <time_frame>2 weeks, 18 weeks, 24 weeks, 40 weeks</time_frame>
    <description>Change in emPHasis-10 score (range 0 - 50, higher scores indicating worse quality of life) between DHEA and placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related side effects and adverse events</measure>
    <time_frame>2 weeks, 18 weeks, 24 weeks, 40 weeks, 42 weeks</time_frame>
    <description>Difference in treatment-related side effects and adverse events (as assessed by CTCAE v4.0) between DHEA and placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>DHEA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DHEA tablet (50 mg) taken by mouth once a day for 18 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 placebo tablet taken by mouth once a day for 18 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DHEA tablet</intervention_name>
    <description>DHEA tablet (50 mg) taken by mouth once a day for 18 weeks.</description>
    <arm_group_label>DHEA</arm_group_label>
    <other_name>Dehydroepiandrosterone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 placebo tablet taken by mouth once a day for 18 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Diagnosis of PAH that is 1) idiopathic, 2) heritable or 3) associated with connective
        tissue disease, congenital systemic-to-pulmonary shunt, porto-pulmonary hypertension, drug
        or toxin use.

        Documentation of the following at any time prior to study entry:

          -  mPAP ≥ 25 mmHg at rest, pulmonary capillary wedge pressure or left ventricular
             end-diastolic pressure ≤ 15 mmHg, and PVR &gt; 3 Wood units

          -  Pulmonary function testing documenting forced expiratory volume in one second/forced
             vital capacity ratio ≥ 70% predicted and total lung capacity ≥ 70% predicted

          -  Chest tomography documenting absence of parenchymal lung disease

          -  Normal or low probability V/Q scan

        Exclusion Criteria:

          -  Age &lt; 18 years old

          -  PAH associated with human immunodeficiency virus infection

          -  New background PAH therapy within 12 weeks

          -  Significant dose change in background PAH therapy within 12 weeks.

          -  Untreated severe obstructive sleep apnea diagnosed by polysomnography

          -  Evidence of left-sided valvular disease or systolic dysfunction on echocardiogram (≥
             moderate mitral or aortic disease or LV ejection fraction ≤ 50%)

          -  Glomerular filtration rate &lt;40 mls/min/1.73m2

          -  Child-Pugh Class C cirrhosis

          -  Untreated hypo- or hyper-thyroidism

          -  Pregnant or breastfeeding

          -  Active or planned use of hormone supplements, oral contraceptive pills, hormonal
             therapies

          -  History of breast, ovarian, uterine, testicular or prostate cancer

          -  Current use of another investigational PAH therapy

          -  Contraindication to MRI (e.g., metal device or fragment)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corey E Ventetuolo, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brown University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Walsh</last_name>
    <phone>401-444-4833</phone>
    <email>thomas.walsh@lifespan.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amy Palmisciano</last_name>
    <phone>401-444-4961</phone>
    <email>apalmisciano@lifespan.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rhode Island Hospital Pulmonary Hypertension Center</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas P Walsh</last_name>
      <phone>401-444-4833</phone>
      <email>thomas.walsh@lifespan.org</email>
    </contact>
    <contact_backup>
      <last_name>Amy Palmisciano, RN</last_name>
      <phone>4014442733</phone>
      <email>apalmisciano@lifespan.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>August 10, 2018</study_first_submitted>
  <study_first_submitted_qc>August 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2018</study_first_posted>
  <last_update_submitted>October 21, 2019</last_update_submitted>
  <last_update_submitted_qc>October 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dehydroepiandrosterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 23, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT03648385/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

